GDC-0927(SRN-927)是一种新型,强效,非甾体类且口服生物可利用的选择性雌激素受体拮抗剂。
CAS：1642297-01-5
分子式：C28H28FNO4
分子量：461.52
纯度：98%
存储：Store at -20°C

Background:

GDC-0927 (SRN-927) is a novel, potent, non-steroidal, orally bioavailable, selective estrogen receptor antagonist.

GDC-0927 is a novel, potent, non-steroidal, orally bioavailable, selective ER antagonist/ER degrader (SERD) that induces tumor regression in estrogen receptor (ER)+breast cancer (BC) patient-derived xenograft models[1].

[1]. MN Dickler, et al. Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC). AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD5-10.